

AMENDMENTS TO THE SPECIFICATION

Prior to an examination of the above-identified patent application, the Examiner is respectfully requested to amend the Specification, as follows:

Please replace the paragraph appearing at page 1, line 30 through page 2, line 12, with the following amended paragraph:

As another approach for solution, researches have been made for providing a microcirculation property and escapability from RES by modification of membrane surfaces of liposomes with a glycolipid, glycoprotein, amino acid-lipid, polyethylene glycol-lipid or the like. Substances for the modification so far reported include, for example, glycophon (The Pharmaceutical Society of Japan, the 106th Annual Meeting, Summaries of Symposia, p.336, 1986), ganglioside GM1 (FEBS Letters, Vol. 223, p.42, 1987), phosphatidylinositol (FEBS Letters, Vol. 223, p.42, 1987), glycophon and ganglioside GM3 (Japanese Patent Unexamined Publication (Kokai) No. 63-221837), polyethylene glycol derivative (FEBS Letters, Vol. 268, p.235, 1990), glucuronic acid derivative (Chemical & Pharmaceutical Bulletin, Vol. 38, p.1663, 1990), glutamic acid derivative (Biochimica et Biophysica Acta, Vol. 1108, p.257, 1992), polyglycerin phospholipid derivative (Japanese Patent Unexamined Publication No. 6-228012), and the like.

Please replace the paragraph appearing at page 35, line 13, through page 36, line 1, with the following amended paragraph:

An experiment for evaluation of circulating in blood was performed in SD male rats (6-week old) using Examples 1 to 5 and Control Examples 1 to 4 mentioned above. Each liposome dispersion was administered to rats from the cervical vein under ether anesthesia (each group consisted of 5 animals, dose: 7.5 mg doxorubicin/5 mL/kg), then blood was collected in heparin (0.5 to 1 mL) from the cervical vein under ether anesthesia at each blood collection time (2, 4, 8, 24, 48, 72, 120, 168 hours) and subjected to plasma skimming. Then, in a conventional manner, the blood was pretreated, and plasma medicament concentration was measured by HPLC. The AUC (0 to  $\infty$ ) was calculated from the plasma medicament concentration obtained with each formulation of liposome dispersion according to the trapezoidal rule. As shown in Table 1, AUCs larger by 1 order or more were obtained with the liposome formulations containing the phospholipid derivatives of the present invention (Examples 1 to 5) compared with AUCs obtained with the liposomes of Control Example 1 not containing the lipid derivative of the present invention, the liposomes of Control Example 2 added only with the phospholipid portion (DSPE: distearoylphosphatidylethanolamine) of the lipid derivative of the present invention, and the liposomes of Control Examples 3 and 4 added with the polyglycerin lipid derivatives disclosed in Japanese Patent Unexamined Publication (KOKAI) No. ~~6-22802~~ 6-228012 and literature (International Journal of Pharmacology, Vol. 111, page 103, 1994), and thus clearly longer circulating in the blood was observed with the liposome formulations containing the phospholipid derivatives of the present invention.

Please replace the paragraph appearing at page 43, line 24 - 26, with the following amended paragraph:

For Control Examples 14 and 15, the polyglycerin lipid derivatives disclosed in Japanese Patent Unexamined Publication (KOKAI) No. ~~6-22802~~ 6-228012 and the literature (International Journal of Pharmacology, Vol. 111, pages 103, 1994) were used.